Lindsey Shapiro, PhD, Science Writer —

Treatment with Livmarli (maralixibat) leads to significant clinical benefits for people with progressive familial intrahepatic cholestasis (PFIC) across a wide range of disease…

Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among women and Asian minorities living…

Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver damage, in children and adolescents…

Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…

Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…

FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…

The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…

Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…

Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…

Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…